Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

Metsera is a new GLP-1 player with a Phase 2b injectable and promising oral and amylin drugs in development. Learn why MTSR ...

A novel investigational endoscopic procedure targeting the duodenum appears beneficial in improving glycemic parameters in ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

HealthDay News — For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes, according to a study ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Ready to transform your body? It's possible with this program's personalized care, telehealth consultations, and semaglutide ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...